Top Stories
Company Results | JBM Healthcare (2161 HK/BUY/HK$1.96/Target: HK$3.10)
JBM’s FY26 revenue grew 6.7% yoy to HK$834m, largely in line with our estimate, but net profit (up 1.9% yoy to HK$201m) missed our expectation by 6% on forex losses and higher non-controlling interest. Management remains conservative on FY27 and plans to continue focusing on brand building for its proprietary brands through omni-channel marketing as well as sales channel enhancement. Maintain BUY and cut target price to HK$3.10 as we roll over to 12.0x FY27F PE.
Technical Analysis
MiniMax Group | 100 HK
Support levels: HK$377.00/HK$235.00
Resistance levels: HK$640.00/HK$651.00
Ubtech Robotics | 9880 HK
Support levels: HK$84.60/HK$75.90
Resistance levels: HK$110.70/HK$114.50
Top Stories
Company Results | JBM Healthcare (2161 HK/BUY/HK$1.96/Target: HK$3.10)
JBM’s FY26 revenue grew 6.7% yoy to HK$834m, largely in line with our estimate, but net profit (up 1.9% yoy to HK$201m) missed our expectation by 6% on forex losses and higher non-controlling interest. Management remains conservative on FY27 and plans to continue focusing on brand building for its proprietary brands through omni-channel marketing as well as sales channel enhancement. Maintain BUY and cut target price to HK$3.10 as we roll over to 12.0x FY27F PE.
Technical Analysis
MiniMax Group | 100 HK
Support levels: HK$377.00/HK$235.00
Resistance levels: HK$640.00/HK$651.00
Ubtech Robotics | 9880 HK
Support levels: HK$84.60/HK$75.90
Resistance levels: HK$110.70/HK$114.50
IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS
This report is provided subject to, and must be read together with, the full Disclosures / Disclaimers available at the following link: https://research-api.uobkayhian.com/assets/disclaimer/0e6d602f-adeb-45f8-9dea-5d5591daae87, which are incorporated by reference into this report. In particular, this report is intended for general circulation and informational purposes only and does not constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report. By accessing, receiving or using this report, you acknowledge that you have read, understood and agreed to be bound by the Disclosures / Disclaimers, as may be amended, supplemented or updated from time to time.
